Resolian

Alliance Pharma and Drug Development Solutions are rebranding as Resolian.

We’re fusing our expertise, increasing our offerings, and renewing our commitment to world-class scientific solutions.

Proven Expertise. Worldwide Access.

We are Resolian.

For the latest news and updates, visit our LinkedIn profile linkedin.com/company/drugde…

Following the recent requirements regarding risk assessments of marketed products, a significant amount of small molecule related APIs, possibly 30%+, have been shown to have the potential to form active related nitrosamines.

Read the blog > buff.ly/3GF909w

Upcoming webinar
🖥 Challenges of developing ADA and concentration (PK or PD) assays for lysosomal transgene enzymes on an automated immunoassay platform
📆 January 26, 2023 (08:00 PST; 11:00 EST; 16:00 GMT; 17:00 CET)
📍 Online
✔ Learn more and register: buff.ly/3vA2vOD

Supporting your DDI studies

We have built a portfolio of in-house quantitative LC-MS/MS assays, with an emphasis on the probe drugs and inducers/inhibitors recommended in guidance issued by the EMA and FDA.

✔ Learn more: buff.ly/3GcqaK5